Tirzepatide
Zepbound · Mounjaro
Semaglutide
Wegovy · Ozempic · Rybelsus
Side by side
| Tirzepatide | Semaglutide | |
|---|---|---|
| Class | GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brands | Zepbound, Mounjaro | Wegovy, Ozempic, Wegovy pill, Rybelsus |
| Forms | weekly injection | weekly injection or daily tablet |
| Half-life | About 5 days, which is why it's dosed once a week | About 1 week for the injection, so steady levels take 4 to 5 weeks |
| Weight trial (highest dose) | 20.9% (SURMOUNT-1, 72 wk) | 14.9% (STEP 1, 68 wk) |
| Head-to-head (SURMOUNT-5) | about 20.2% | about 13.7% |
| Nausea, weight labels | 25% to 29% | 44% |
The main difference
Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1. Semaglutide acts on GLP-1 only. In SURMOUNT-5, a 72-week head-to-head trial published in 2025, adults with obesity lost an average of about 20.2% on tirzepatide vs about 13.7% on semaglutide. That's the only direct comparison; other figures come from separate trials.
Trial weight loss
Explainer · 0:23
Read the transcript
- After you eat, your gut releases a hormone called GLP-1. GLP-1 medicines copy it, but last much longer in the body.
- It slows how fast your stomach empties, so you feel full sooner and stay full for longer.
- It also acts on appetite centers in the brain, which quiets hunger and constant thoughts about food.
- When blood sugar is high, it helps the pancreas release insulin. Tirzepatide also acts on a second gut hormone, GIP.
How to use it
- Enter your numbers. Switch between US and metric units at any time.
- Results update as you type, and the formula is shown so you can check it.
- Copy the link, save the plan on this device, or print it for your next appointment.

These are estimates, not a diagnosis. A clinician can account for your health history and medicines.
Common questions
Is tirzepatide stronger than semaglutide?
In SURMOUNT-5, a 72-week head-to-head trial published in 2025, adults with obesity lost an average of about 20.2% on tirzepatide vs about 13.7% on semaglutide. That's the only direct comparison; other figures come from separate trials.
Are tirzepatide and semaglutide the same?
No. Tirzepatide targets GIP and GLP-1 receptors; semaglutide targets GLP-1 only.
Sources
Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error